Download PDF

1. Company Snapshot

1.a. Company Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip.It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.


The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools.It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets.Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on TWST

Breaking News: Twist Bioscience Corporation announced the launch of research-grade Plasmid DNA Preps to support pre-clinical studies in pharmaceutical and biotech customers. The new plasmid preps offer quality, consistency, speed and cost efficiency. CEO Emily M. Leproust stated that the preps meet customer expectations. This new product launch aims to advance nucleic acid therapeutics research. No recent earnings release data available. Analysts at Zacks recommend a hold. Analysts at Wedbush recommend a outperform.

1.c. Company Highlights

2. Twist Bioscience's Q4 2025 Earnings: A Strong Finish to a Record Year

Twist Bioscience reported Q4 2025 revenue of $99 million, a 17% year-over-year increase, exceeding guidance, with an eleventh consecutive quarter of growth. The full-year revenue was $376.6 million, up 20% from fiscal 2024. Gross margin for Q4 was 51.3%, and 50.7% for the full year, up from 42.6% in fiscal 2024. The company's actual EPS loss was $0.45, better than the estimated loss of $0.5.

Publication Date: Nov -16

📋 Highlights
  • Revenue Growth:: Q4 revenue reached $99 million, a 17% YoY increase, while full-year revenue hit $376.6 million, up 20% YoY.
  • Gross Margin Expansion:: Full-year gross margin improved to 50.7% (up from 42.6% in 2024), with Q4 at 51.3%.
  • Adjusted EBITDA Path:: Q4 adjusted EBITDA loss narrowed to $7.8 million; expects breakeven by Q4 2026 with $46.9M full-year 2025 loss.
  • Product Launch Impact:: MRD Express product, launching in 2026, aims to boost NGS growth (1–2% contribution in fiscal 2026) with 12-hour turnaround.
  • 2026 Guidance:: Revenue projected at $425–435 million (13–15.5% YoY growth), with DNA synthesis/protein solutions expected to reach $194–199 million.

Segment Performance

The company's Synbio revenue was $39.5 million, up 17% year-over-year, driven by the Express portfolio, which offers rapid turnaround time, high quality, and scalability. NGS revenue was $53 million, up 16% year-over-year, driven by commercial success from diagnostic customers' clinical assays. Biopharma services revenue was $6.4 million, up 22% year-over-year, with orders of $11.5 million.

Guidance and Outlook

Twist Bioscience expects to achieve adjusted EBITDA breakeven by the end of fiscal 2026. For fiscal 2026, total revenues are expected to be $425 million to $435 million, with growth of 13% to 15.5% year over year. The DNA synthesis and protein solutions group is expected to generate $194 million to $199 million in revenue, with 15% to 18% growth, while the NGS applications group is expected to generate $231 million to $236 million in revenue, with 11% to 13.5% growth.

Valuation and Metrics

With a P/S Ratio of 4.31 and an EV/EBITDA of -12.08, the market seems to be pricing in a significant growth story. The company's guidance for fiscal 2026 and its expectation to achieve adjusted EBITDA breakeven by the end of the year support this narrative. Analysts estimate next year's revenue growth at 15.0%, which is in line with the company's guidance.

New Product Introductions

The company is introducing new products, including an express product for minimal residual disease (MRD), expected to launch commercially in early 2026. This product aims to empower customers in cancer diagnosis monitoring and treatment. The MRD Express product is expected to have a significant impact on the market, with a 12-hour turnaround time and sensitivity enhancements from tumor-informed approach.

3. NewsRoom

Card image cap

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Dec -04

Source: businesswire.com

Card image cap

Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm

Dec -03

Source: globenewswire.com

Card image cap

Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade

Dec -01

Source: investorplace.com

Card image cap

Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength

Nov -18

Source: seekingalpha.com

Card image cap

Can Twist Bioscience Drop More?

Nov -17

Source: forbes.com

Card image cap

Twist Bioscience (NASDAQ:TWST) Hits New 12-Month Low Following Weak Earnings

Nov -15

Source: defenseworld.net

Card image cap

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

Nov -14

Source: seekingalpha.com

Card image cap

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Nov -14

Source: benzinga.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.97%)

6. Segments

Next Generation Sequencing Tools

Expected Growth: 15%

Twist Bioscience's Next Generation Sequencing (NGS) tools are driven by increasing adoption in precision medicine, liquid biopsy, and gene therapy. Growing demand for genetic data, advancements in synthetic biology, and declining sequencing costs also contribute to the 15% growth. Additionally, Twist's unique silicon-based DNA synthesis technology and partnerships with industry leaders further accelerate growth.

Synthetic Genes

Expected Growth: 16%

Twist Bioscience's synthetic genes segment growth is driven by increasing demand for gene therapy and synthetic biology research, accelerated by the COVID-19 pandemic. The company's unique silicon-based DNA synthesis platform enables rapid, high-throughput gene synthesis, fueling growth in the genomics and biotech industries.

Antibody Discovery

Expected Growth: 14%

Twist Bioscience's Antibody Discovery segment growth is driven by increasing adoption of synthetic biology tools, rising demand for targeted therapies, and growing partnerships with biopharma companies. The 14% growth rate is also fueled by the company's expanding library of antibodies, improved discovery workflows, and increasing investments in research and development.

Oligo Pools

Expected Growth: 13%

Twist Bioscience's Oligo Pools growth is driven by increasing adoption in synthetic biology, gene editing, and NGS applications. Rising demand for precision medicine, gene therapy, and COVID-19 research fuels growth. Additionally, Twist's unique silicon-based DNA synthesis platform enables high-throughput, cost-effective, and high-quality oligo production, further accelerating market penetration.

DNA Libraries

Expected Growth: 12%

Twist Bioscience's DNA Libraries segment growth is driven by increasing adoption in synthetic biology, gene therapy, and precision medicine. Rising demand for novel therapeutics, advancements in gene editing technologies, and growing investments in biotech research and development are key contributors to this 12% growth.

7. Detailed Products

Synthetic DNA

Twist Bioscience's synthetic DNA products are designed to provide high-quality, custom-made DNA sequences for various applications, including gene synthesis, genome editing, and synthetic biology.

Gene Fragments

Twist Bioscience's gene fragments are high-quality, custom-made DNA sequences that can be used to build genes, pathways, and genomes.

Oligo Pools

Twist Bioscience's oligo pools are high-diversity, custom-made pools of DNA oligonucleotides that can be used for various applications, including CRISPR-Cas9 genome editing and gene regulation.

Target Enrichment

Twist Bioscience's target enrichment products are designed to selectively enrich for specific genomic regions of interest, enabling cost-effective and efficient sequencing.

Exome Enrichment

Twist Bioscience's exome enrichment products are designed to selectively enrich for protein-coding regions of the genome, enabling efficient and cost-effective exome sequencing.

8. Twist Bioscience Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Twist Bioscience Corporation's proprietary DNA synthesis technology and high-quality gene synthesis products make it difficult for substitutes to emerge, reducing the threat of substitutes.

Bargaining Power Of Customers

While customers have some bargaining power due to the availability of alternative gene synthesis providers, Twist Bioscience Corporation's strong brand reputation and high-quality products mitigate this power.

Bargaining Power Of Suppliers

Twist Bioscience Corporation's vertical integration and in-house manufacturing capabilities reduce its dependence on suppliers, minimizing their bargaining power.

Threat Of New Entrants

While the gene synthesis market is growing, high barriers to entry, including significant capital expenditures and regulatory hurdles, make it challenging for new entrants to compete with Twist Bioscience Corporation.

Intensity Of Rivalry

The gene synthesis market is highly competitive, with several established players, including Twist Bioscience Corporation, competing for market share and customer loyalty.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 13.11%
Debt Cost 3.95%
Equity Weight 86.89%
Equity Cost 12.06%
WACC 11.00%
Leverage 15.09%

11. Quality Control: Twist Bioscience Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
LabCorp

A-Score: 5.5/10

Value: 3.7

Growth: 4.3

Quality: 5.1

Yield: 2.0

Momentum: 8.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
Medpace

A-Score: 4.8/10

Value: 1.3

Growth: 9.2

Quality: 8.1

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Natera

A-Score: 4.5/10

Value: 4.0

Growth: 7.1

Quality: 3.3

Yield: 0.0

Momentum: 7.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Waters

A-Score: 3.9/10

Value: 1.5

Growth: 5.2

Quality: 7.5

Yield: 0.0

Momentum: 3.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Twist Bioscience

A-Score: 3.6/10

Value: 6.8

Growth: 6.1

Quality: 4.8

Yield: 0.0

Momentum: 2.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Charles River Laboratories

A-Score: 3.3/10

Value: 4.7

Growth: 4.1

Quality: 3.1

Yield: 0.0

Momentum: 3.5

Volatility: 4.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

32.38$

Current Price

32.38$

Potential

-0.00%

Expected Cash-Flows